Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene

Clinical Genetics

Volumn 55, Issue 5, 1999, Pages 289-304

  Meyn, M Stephen ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Apoptosis; Ataxia telangiectasia; ATM; Breast cancer; Cell cycle checkpoints; Leukemia

Indexed keywords

APOPTOSIS; ATAXIA TELANGIECTASIA; CANCER; CELL CYCLE; GENE; GENETIC RECOMBINATION; HUMAN; IMMUNE DEFICIENCY; NERVE DEGENERATION; PATHOLOGY; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATAXIA TELANGIECTASIA; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; HUMANS; LEUKEMIA; MALE; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; TUMOR SUPPRESSOR PROTEINS;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0033021504     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.1999.550501.x     Document Type: Review

References (183)

1. Battista JR, Donnelly CE, Ohta T, Walker GC. The SOS response and induced mutagenesis. Prog Clin Biol Res 1990: 340A: 169-178.
2. Louis-Bar D. Sur un syndrome progressif comprenant des télangiectasies capillaires cutanées et conjonctivales symétriques, a disposition naevode et de troubles cérébelleux. Confin Neurol (Basel) 1941: 4: 32-42.
3. Meyn MS. The chromosome instability syndromes: lessons for carcinogenesis. Curr Top Microbiol Immunol 1997: 221: 71-148.
4. Sedgwick RP, Boder E, Ataxia-Telangiectasia. In: deJong JMBV, ed. Hereditary Neuropathies and Spinocerebellar Atrophies. New York: Elsevier, 1991: 347-423. (Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology, vol 16).
5. Sedgwick RP, Boder E, Ataxia-Telangiectasia. In: deJong JMBV, ed. Hereditary Neuropathies and Spinocerebellar Atrophies. New York: Elsevier, 1991: 347-423. (Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology, vol 16).
6. Cabana MD, Crawford TO. Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics 1998: 102: 98-100.
7. Peterson RDA, Good RA. Ataxia-telangiectasia. In: Bergsma D, Good RA, eds. Birth Defects - Immunologic Deficiency Disease in Man, vol 4. New York: National Foundation, March of Dimes, 1968: 370-377.
8. Strober W, Wochner RD, Barlow MH, McFarlin DE, Waldmann TA. Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest 1968: 47: 1905-1915.
9. Li A, Huang Y, Swift M. Mutation types and the survival of A-T patients. In: Gatti R, Concannon P, eds. Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas, NV, 1999.
10. Peterson RD, Funkhouser JD, Tuck-Muller CM, Gatti RA. Cancer susceptibility in ataxia-telangiectasia. Leukemia 1992: 6 (Suppl. 1): 8-13.
11. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986: 77: 89-92.
12. Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 1990: 46: 9-19.
13. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol 1998: 31: 491-497.
14. Taylor AM. Ataxia telangiectasia genes and predisposition to leukaemia, lymphoma and breast cancer. Br J Cancer 1992: 66: 5-9.
15. Spector BD, Filipovick AH, Perry GS III, Kersey JH. Epidemiology of cancer in ataxia-telangiectasia. In: Bridges BA, Harnden DG, eds. Ataxia-Telangiectasia. New York: John Wiley and Sons Ltd, 1982: 103-138.
16. Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med 1992: 82: 169-179.
17. Strich S. Pathological findings in 3 cases of ataxia-telangiectasia. Acta Neurol Scand 1963: 42: 354-366.
18. Aguilar MJ, Kamoshita S, Landing BH, Boder E, Sedgwick RP. Pathological observations in ataxia-telangiectasia. A report on 5 cases. J Neuropathol Exp Neurol 1968: 27: 659-676.
19. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 1970: 282: 1396-1402.
20. Cohen MM, Levy HP. Chromosome instability syndromes. Adv Human Genet 1989: 18: 43-149.
21. Kojis TL, Gatti RA, Sparkes RS. The cytogenetics of ataxia telangiectasia. Cancer Genet Cytogenet 1991: 56: 143-156.
22. Aurias A, Dutrillaux B, Buriot D, Lejeune J. High frequencies of inversions and translocations of chromosome 7 and 14 in ataxia telangiectasia. Mut Res 1980: 69: 369-374.
23. Pfeiffer RA. Chromosomal abnormalities in ataxia-telangiectasia (Louis Bar's Syndrome). Humangenetik 1970: 8: 302-306.
24. Hayashi K, Schmid W. Tandem duplication of q14 and dicentric formation by end-to-end chromosome fusion in ataxia telangiectasia. Humangenetik 1975: 30: 135-141.
25. Taylor AMR, Oxford JM, Metcalfe JA. Spontaneous cytogenetic abnormalities in lymphocytes from thirteen patients with ataxia telangiectasia. Int J Cancer 1981: 27: 311-319.
26. Smilenov LB, Morgan SE, Mellado W, Sawant SG, Kastan MB, Pandita TK. Influence of ATM function on telomere metabolism. Oncogene 1997: 15: 2659-2665.
27. Metcalfe JA, Parkhill J, Campbell L et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet 1996: 13: 350-353.
28. Pandita TK, Pathak S, Geard CR. Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells. Cytogenet Cell Genet 1995: 71: 86-93.
29. Bigbee WL, Langlois RG, Swift M, Jensen RH. Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet 1989: 44: 402-408.
30. Lipkowitz S, Stern MH, Kirsch IR. Hybrid T cell receptor genes formed by interlocus recombination in normal and ataxia-telangiectasis lymphocytes. J Exp Med 1990: 172: 409-418.
31. Kobayashi Y, Tycko B, Soreng AL, Sklar J. Transrearrangements between antigen receptor genes in normal human lymphoid tissues and in ataxia telangiectasia. J Immunol 1991: 147: 3201-3209.
32. Lipkowitz S, Garry VF, Kirsch IR. Interlocus V-J recombination measures genomic instability in agriculture workers at risk for lymphoid malignancies. Proc Natl Acad Sci USA 1992: 89: 5301-5305.
33. Cole J, Arlett CF. Cloning efficiency and spontaneous mutant frequency in circulating T-lymphocytes in ataxiatelangiectasia patients. Int J Radiat Biol 1994: 66: S123-S131.
34. Meyn MS. High spontaneous intrachromosomal recombination rates in ataxia-telangiectasia. Science 1993: 260: 1327-1330.
35. Luo CM, Tang W, Mekeel KL, DeFrank JS, Anne PR, Powell SN. High frequency and error-prone DNA recombination in ataxia telangiectasia cell lines. J Biol Chem 1996: 271:4497-4503.
36. Gotoff SP, Amirmokri E, Liebner EJ. Neoplasia, untoward response to X-irradiation, and tuberous sclerosis. Am J Dis Child 1967: 114: 617-625.
37. Morgan JL, Holcomb TM, Morrissey RW. Radiation reaction in ataxia telangiectasia. Am J Dis Child 1968: 116: 557-558.
38. Feigin RD, Vietti TJ, Wyatt RG, Kaufman DG, Smith CH, Jr. Ataxia telangiectasia with granulocytopenia. J Pediatr 1970: 77: 431-438.
39. Eyre JA, Gardner-Medwin D, Summerfield GP. Leukoencephalopathy after prophylactic radiation for leukaemia in ataxia telangiectasia. Arch Dis Child 1988: 63: 1079-1080.
40. Cornforth MN, Bedford JS. On the nature of a defect in cells from individuals with ataxia-telangiectasia. Science 1985: 227: 1589-1591.
41. Pandita TK, Hittelman WN. Initial chromosome damage but not DNA damage is greater in ataxia telangiectasia cells. Radiat Res 1992: 130: 94-103.
42. Arlett CF, Green MH, Priestley A, Harcourt SA, Mayne LV. Comparative human cellular radiosensitivity: I. The effect of SV40 transformation and immortalisation on the gamma-irradiation survival of skin derived fibroblasts from normal individuals and from ataxia-telangiectasia patients and heterozygotes. Int J Radiat Biol 1988: 54: 911-928.
43. 0) T-lymphocytes, T-lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients and from ataxia-telangiectasia heterozygotes. Int J Radiat Biol 1988: 54: 929-943.
44. Shiloh Y, Tabor E, Becker Y. The response of ataxia-telangiectasia homozygous and heterozygous skin fibroblasts to neocarzinostatin. Carcinogenesis 1982: 3: 815-820.
45. Burger RM, Drlica D, Birdsall B. The DNA cleavage of iron bleomycin. J Biol Chem 1994: 269: 25978-25985.
46. Nelson WG, Kastan MB. DNA strand breaks, the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994: 14: 1815-1823.
47. Taylor AMR, Harnden DG, Arlett CF, Harcourt A, Lehmann AR, Stevens S, Bridges BA. Ataxia telangiectasia: a human mutation with abnormal radiation senstivity. Nature 1975: 258: 427-428.
48. Lehman AR, Stevens S. The production and repair of double strand breaks in cells from normal humans and from patients with ataxia telangiectasia. Biochim Biophys Acta 1977: 474: 49-60.
49. Muriel WJ, Lamb JR, Lehmann AR. UV mutation spectra in cell lines from patients with Cockayne's syndrome and ataxia telangiectasia, using the shuttle vector pZ189. Mutat Res 1991: 254: 119-123.
50. Eady JJ, Peacock JH, McMillan TJ. Host cell reactivation of gamma-irradiated adenovirus 5 in human cell lines of varying radiosensitivity. Br J Cancer 1992: 66: 113-118.
51. Debenham PG, Webb MB, Stretch A, Thacker J. Examination of vectors with two dominant, selectable genes for DNA repair and mutation studies in mammalian cells. Mutat Res 1988: 199: 145-158.
52. Cox R, Masson WK, Debenham PG. Webb MBT. The use of recombinant DNA plasmids for the determination of DNA-repair and recombination in cultured mammalian cells. Br J Cancer 1984: 46 (Suppl. VI): 67-72.
53. Blocher D. Sigut D, Hannan MA. Fibroblasts from ataxia telangiectasia (AT) and AT heterozygotes show an enhanced level of residual DNA double-strand breaks after low dose-rate gamma-irradiation as assayed by pulsed field gel electrophoresis. Int J Radiat Biol 1991: 60: 791-802.
54. Taylor AMR. Unrepaired DNA strand breaks in irradiated ataxia-telangiectasia lymphocytes suggested from cyctogenetic observations. Mutat Res 1978: 50: 407-418.
55. Taylor AM, Metcalfe JA, McConville C. Increased radiosensitivity and the basic defect in ataxia telangiectasia. Int J Radiat Biol 1989: 56: 677-684.
56. Pandita TK, Hittelman WN. The contribution of DNA and chromosome repair deficiencies to the radiosensitivity of ataxia-telangiectasia. Radiat Res 1992: 131: 214-223.
57. Humar B, Muller H, Scott RJ. Elevated frequency of p53-independent apoptosis after irradiation increases levels of DNA breaks in ataxia telangiectasia lymphoblasts. Int J Radiat Biol 1997: 72: 257-269.
58. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls. Nature 1992: 359: 599-604.
59. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994: 266: 1821-1828.
60. Kastan MB, Zhan Q, el-Deiry WS et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992: 71: 587-597.
61. Painter RB, Young BR. Radiosensitivity in ataxia-telang-iectasia: a new explanation. Proc Natl Acad Sci USA 1980: 77: 7215-7217.
62. Zambeti-Bosseler F, Scott D. Cell death, chromosome damage and mitotic delay in normal human, ataxia telangiectasia and retinoblastoma fibroblasts after X-irradiation. Intl J Radiat Biol 1980: 39: 547-558.
63. Rudolph NS, Latt SA. Flow cytometric analysis of X-ray sensitivity in ataxia telangiectasia. Mutat Res 1989: 211: 31-41.
64. Beamish H, Lavin MF. Radiosensitivity in ataxia-telangiectasia: anomalies in radiation-induced cell cycle delay. Int J Radiat Biol 1994: 65: 175-184.
65. Takagi M, Delia D, Chessa L, Iwata S, Shigeta T, Kanke Y, Goi K, Asada M, Eguchi M, Kodama C, Mitzutani S. Defective control of apoptosis, radiosensitivity, and spindle checkpoint in ataxia telangiectasia. Cancer Res 1998: 58: 4923-4929.
66. Khanna KK, Lavin MF. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 1993: 8: 3307-3312.
67. Canman CE, Wolff AC, Chen CY, Fornace AJ Jr, Kastan MB. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994: 54: 5054-5058.
68. Cheng X, Cheong N, Wang Y, Iliakis G. Ionizing radiation-induced phosphorylation of RPA p34 is deficient in ataxia telangiectasia and reduced in aged normal fibroblasts. Radiother Oncol 1996: 39: 43-52.
69. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshaw-Boris A, Kastan MB, Wang JY. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997: 387: 516-519.
70. Jung M, Kondratyev A, Lee SA, Dimtchev A, Dritschilo A. ATM gene product phosphorylates I kappa B-alpha. Cancer Res 1997: 57: 24-27.
71. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y. Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998: 281: 1674-1677.
72. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998: 281: 1677-1679.
73. Gately DP, Hittle JC, Chan GKT, Yen TJ. Characterization of ATM expression, localization, and associated DNA-dependent protein kinse activity. Mol Biol Cell 1998: 9: 2361-2374.
74. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K, Taya Y, Gabrielli B, Chan D, Lees-Miller SP, Lavin MF. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998: 20: 398-400.
75. Lee SJ, Dimtchev A, Lavin MF, Dritschilo A, Jung M. A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappaB. Oncogene 1998: 17: 1821-1826.
76. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 1998: 19: 175-178.
77. Matsuoka S, Huang M, Elledge S. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1999: 282: 893-897.
78. Meyn MS, Strasfeld L, Allen C. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiectasia. Int J Radiat Biol 1994: 66: S141-S149.
79. Meyn MS. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res 1995: 55: 5991-6001.
80. Fritz E, Elsea SH, Patel PI, Meyn MS. Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectasia phenotype. Proc Natl Acad Sci USA 1997: 94: 4538-4542.
81. Ramsay J, Birrell G, Baumann K, Bodero A, Parsons P, Lavin M. Radiosensitive melanoma cell line with mutation of the gene for ataxia telangiectasia. Br J Cancer 1998: 77: 11-14.
82. Jung M, Zhang Y, Dimtchev A, Dritschilo A. Impaired regulation of nuclear factor-kappaB results in apoptosis induced by gamma radiation. Radiat Res 1998: 149: 596-601.
83. Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 1996: 10: 2411-2422.
84. Barlow C, Liyanage M, Moens PB, Deng CX, Ried T, Wynshaw-Boris A. Partial rescue of the prophase I defects of Atm-deficient mice by p53 and p21 null alleles. Nat Genet 1997: 17: 462-466.
85. Wang YA, Elson A, Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 1997: 94: 14590-14595.
86. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crawley JN, Ried T, Tagle D, Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996: 86: 159-171.
87. Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 1996: 10: 2401-2410.
88. Westphal CH, Rowan S. Schmaltz C. Elson A, Fisher DE, Leder P, Atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat Genet 1997: 16: 397-401.
89. Herzog KH, Chong MJ, Kapsetaki M, Morgan JI, McKinnon PJ. Requirement for Aim in ionizing radiation-induced cell death in the developing central nervous system. Science 1998: 280: 1089-1091.
90. Karlseder J, Broccoli D, Dai Y, Hardy S. de Lange T. p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999: 283: 1321-1324.
91. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995: 268: 1749-1753.
92. + gene of Schizosaccharomyces pombe is involved in multiple checkpoint functions and in DNA repair. Proc Natl Acad Sci USA 1992: 89: 4952-4956.
93. Weinert TA, Kiser GL, Hartwell LH. Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes Dev 1994: 8: 652-665.
94. Hari KL, Santerre A, Sekelsky JJ, McKim KS, Boyd JB, Hawley RS. The mei-41 gene of D. melanagasier is a structural and functional homolog of the human ataxia telangiectasia gene. Cell 1995: 82: 815-821.
95. Phipps J, Nasim A, Miller DR. Recovery, repair, and mutagenesis in Schizosaccharomyces pombe. Adv Genet 1985: 23: 1-72.
96. Greenwell PW. Kronmal SL. Porter SE, Gassenhuber J, Obermaier B, Petes TD. TEL1, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell 1995: 82: 823-829.
97. Jaspers NG. Gatti RA, Baan C, Linssen PC, Bootsma D. Genetic complementation analysis of ataxia telangiectasia and Nijmegen breakage syndrome: a survey of 50 patients. Cytogenet Cell Genet 1988: 49: 259-263.
98. Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, Gatti RA, Jorgensen TJ, Shiloh Y, Bar-Shira A. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet 1998: 62: 551-561.
99. Gilad S, Bar-Shira A, Harnik R, Shkedy D, Ziv Y, Khosravi R, Brown K, Vanagaite L, Xu G, Frydman M, Lavin MF, Hill D, Tagle DA, Shiloh Y. Ataxia-telangiectasia: founder effect among north African Jews. Hum Mol Genet 1996: 5: 2033-2037.
100. Telatar M, Teraoka S, Wang Z, Chun HH, Liang T, Castellvi-Bel S, Udar N, Borresen-Dale AL, Chessa L, Bernatowska-Matuskiewicz E, Porras O, Watanabe M, Junker A, Concannon P, Gatti RA. Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 1998: 62: 86-97.
101. Chen G, Lee E. The product of the ATM gene is a 370-kDa nuclear phosphoprotein. J Biol Chem 1996: 271: 33693-33697.
102. Soares HD, Morgan JI, McKinnon PJ. Atm expression patterns suggest a contribution from the peripheral nervous system to the phenotype of ataxia-telangiectasia. Neuroscience 1998: 86: 1045-1054.
103. Brown KD, Ziv Y, Sadanandan SN, Chessa L, Collins FS, Shiloh Y, Tagle DA. The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. Proc Natl Acad Sci USA 1997: 94: 1840-1845.
104. Lakin ND, Weber P, Stankovic T, Rottinghaus ST, Taylor AM, Jackson SP. Analysis of the ATM protein in wild-type and ataxia telangiectasia cells. Oncogene 1996: 13: 2707-2716.
105. Watters D, Khanna KK, Beamish H, Birrell G, Spring K, Kedar P. Gatei M, Stenzel D. Hobson K, Kozlov S, Zhang N, Farrell A, Ramsay J, Gatti R, Lavin M. Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms. Oncogene 1997: 14: 1911-1921.
106. Oka A, Takashima S. Expression of the ataxia-telangiectasia gene (ATM) product in human cerebellar neurons during development. Neurosci Lett 1998: 252: 195-198.
107. Keegan KS, Holtzman DA, Plug AW, Christenson ER, Brainerd EE, Flaggs G, Bentley NJ, Taylor EM, Meyn MS, Moss SB, Carr AM, Ashley T, Hoekstra MF. The Atr and Atm protein kinases associate with different sites along meiotically pairing chromosomes. Genes Dev 1996: 10: 2423-2437.
108. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, Campos-Torres J, Leder P. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci USA 1996: 93: 13084-13089.
109. Kuljis RO, Xu Y, Aguila MC, Baltimore D. Degeneration of neurons, synapses, and neuropil and glial activation in a murine Atm knockout model of ataxia-telangiectasia. Proc Natl Acad Sci USA 1997: 94: 12688-12693.
110. Eilam R, Peter Y, Elson A, Rotman G, Shiloh Y, Groner Y, Segal M. Selective loss of dopaminergic nigro-striatal neurons in brains of Atm-deficient mice. Proc Natl Acad Sci USA 1998: 95: 12653-12656.
111. Meyn MS. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res 1995: 55: 5991-6001.
112. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 1997: 71: 1-25.
113. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997: 15: 177-202.
114. Jeggo PA, Carr AM, Lehmann AR. Splitting the ATM: distinct repair and checkpoint defects in ataxia-telangiectasia. Trends Genet 1998: 14: 312-316.
115. Heddle JA, Krepinsky AB, Marshall RR. Cellular sensitivity to mutagens and carcinogens in the chromosome-breakage and other cancer-prone syndromes. In: German J, ed. Chromosome Mutation and Neoplasia. New York: AR Liss, 1983: 203-234.
116. Plug AW, Peters AH, Keegan KS. Hoekstra MF, de Boer P, Ashley T. Changes in protein composition of meiotic nodules during mammalian meiosis. J Cell Sci 1998: 111: 413-423.
117. Kleckner N. Meiosis: how could it work? Proc Natl Acad Sci USA 1996: 93: 8167-8174.
118. Anderson CW. DNA damage and the DNA-activated protein kinase. Trends Biochem Sci 1993: 18: 433-437.
119. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993: 72: 131-141.
120. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D, Lavin MF. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997: 387: 520-523.
121. Rotman G, Shiloh Y. The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surv 1997: 29: 285-304.
122. Lim DS, Kirsch DG, Canman CE, Ahn JH, Ziv Y, Newman LS, Darnell RB, Shiloh Y, Kastan MB. ATM binds to beta-adaptin in cytoplasmic vesicles. Proc Natl Acad Sci USA 1998: 95: 10146-10151.
123. Plug AW, Peters AH, Xu Y, Keegan KS, Hoekstra MF, Baltimore D, de Boer P, Ashley T. ATM and RPA in meiotic chromosome synapsis and recombination. Nat Genet 1997: 17: 457-461.
124. Gatti RL. Ataxia-Telangiectasia: mutations, molecular diagnostics and the possibility of two distinct A-T heterozygous populations. In: Gatti RL, Concannon P, eds. Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas, NV, 1999.
125. Gatti RA, Peterson KL, Novak J, Chen X, Yang-Chen L, Liang T, Lange E, Lange K. Prenatal genotyping of ataxia-telangiectasia. Lancet 1993: 342: 376.
126. Perlman SL. Treatment of ataxia-telangiectasia. Berlin: Springer-Verlag, 1993. (Gatti RA, Painter RB, ed. NATO ASI Series; vol 77).
127. Perlman SL. Treatment of ataxia-telangiectasia. Berlin: Springer-Verlag, 1993. (Gatti RA, Painter RB, ed. NATO ASI Series; vol 77).
128. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996: 92: 130-134.
129. Welcsh PL, Schubert EL, King M-C. Inherited breast cancer: an emerging picture. Clin Genet 1998: 54: 447-458.
130. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997: 15: 307-310.
131. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998: 58: 1376-1379.
132. Reed WB. Epstein WL, Boder E, Sedgwick R. Cutaneous manifestations of ataxia-telangiectasia. JAMA 1966: 195: 746-753.
133. Swift M, Sholman L, Perry M, Chase C. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 1976: 35: 208-215.
134. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987: 316: 1289-1294.
135. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991: 325: 1831-1836.
136. Pippard EC, Hall AJ, Barker DJ, Bridges BA. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 1988: 48: 2929-2932.
137. Borresen AL, Andersen TI, Tretli S, Heiberg A, Moller P. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosom Cancer 1990: 2: 339-340.
138. Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994: 66: S177-S182.
139. Janin N, Andrieu N, Ossian K, Laugé A, Croquette M-F, Griscelli C, Debré M, de Paillerets B, Aurias A, StoppaLyonnet D. Breast cancer risk in AT heterozygotes from 34 French families with an AT affected child. Seventh Ataxia-Telangiectasia Workshop. Clermont-Ferrand, France, 1997.
140. Su Y, Swift M. Mortality of A-T heterozygotes in A-T families. In: Gatti R, Concannon P, eds. Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas, NV, 1999.
141. Forrer R, Chetrit A, Luxenberg O, Shiloh Y, Modan B. Health status of A-T carriers. In: Gatti R, Concannon P, eds. Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas, NV, 1999.
142. Wooster R, Ford D, Mangion J, Ponder BA, Peto J, Easton DF, Stratton MR. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 1993: 92: 91-94.
143. Cortessis V, Ingles S, Millikan R, Diep A. Gatti RA, Richardson L, Thompson WD, Paganini-Hill A, Sparkes RS, Haile RW. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer. Cancer Res 1993: 53: 5083-5086.
144. Easton DF. The inherited component of cancer. Br Med Bull 1994: 50: 527-535.
145. Bishop DT, Hopper J. AT-tributable risks? Nat Genet 1997: 15: 226.
146. Teraoka SN, Malone KE, Concannon P. ATM Mutations in breast cancer patients with early-onset or family history. In: Gatti RA, Concannon P, eds. Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas, NV, 1999.
147. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991: 51: 3075-3079.
148. Nowell PC. The clonal evolution of tumor cell populations. Science 1976: 194: 23-28.
149. Negrini M, Rasio D, Hampton GM, Sabbiolni S, Rattan S, Carter SL, Rosenberg AL, Schwartz GF, Shiloh Y, Cavenee WK, Croce CM. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at Ilq23.3. Cancer Res 1995: 55: 3003-3007.
150. Kerangueven F, Eisinger F, Noguchi T, Allione F, Wargniez V, Eng C, Padberg G, Theillet C, Jacquemier J, Longy M, Sobol H, Birnbaum D. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene 1997: 14: 339-347.
151. Laake K, Odegard A, Andersen TI, Bukholm IK, Karesen R, Nesland JM, Ottestad L, Shiloh Y, Borresen-Dale AL. Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer 1997: 18: 175-180.
152. Rio PG, Pernin D, Bay JO, Albuisson E, Kwiatkowski F, De Latour M, Bernard-Gallon DJ, Bignon YJ. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int J Oncol 1998: 13: 849-853.
153. Waha A, Sturne C, Kessler A, Koch A, Kreyer E, Fimmers R, Wiestler OD, von Deimling A, Krebs D, Schmutzler RK. Expression of the ATM gene is significantly reduced in sporadic breast carcinomas, Int J Cancer 1998: 78: 306-309.
154. Angele S, Vuillaume M, Treilleux I, Bremond A, Gerard J-P, Romestaing P, Hall J. Role of the ATM gene in breast tumor development and radiosensitivity observed in breast cancer patients. In: Gatti RA, Concannon P, eds. Eighth International Workshop on Ataxia-Telangiectasia. Las Vegas. NV, 1999.
155. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster AD, Zaloudik J, Barbanti-Brodano G, James M, Russo G, Croce CM. Negrini M. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 1996: 56: 2726-2732.
156. Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarstrom L, Webster AD, Yuille MA. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997: 17: 96-99.
157. Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Dohner H. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997: 3: 1155-1159.
158. Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H. Garand R, Sigaux F, Stern MH. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 1998: 91: 3920-3926.
159. Yuille MA, Coignet LJ, Abraham SM, Yaqub F, Luo L, Matutes E, Brito-Babapulle V, Vorechovsky I, Dyer MJ, Catovsky D. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene 1998: 16: 789-796.
160. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotpic evolution in CLL: identification of a new sub-group with deletions of 11q and advanced or progressive disease. Leukemia 1995: 9: 2003-2008.
161. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 1998: 58: 4552-4557.
162. Stankovic T, Weber P, Stewart G, Bedenham T. Murray J, Byrd PJ, Moss PAH, Taylor AMR. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999: 353: 26-29.
163. Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol Cell Biol 1997: 17: 2020-2029.
164. Stankovic T, Kidd AM. Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, Haites N, Byrd PJ, Taylor AM. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998: 62: 334-345.
165. Werneke U. Ataxia telangiectasia and risk of breast cancer. Lancet 1997: 350: 739-740.
166. Boice JDJ, Miller RW. Risk of breast cancer in ataxia-telangiectasia. N Engl J Med 1992: 326: 1357-1358.
167. Gray JE. Increased incidence of cancer in a small subset of the population: a new obstacle to screening mammography? Radiology 1992: 185: 285.
168. Kuller LH, Modan B. Risk of breast cancer in ataxia-telangiectasia. N Engl J Med 1992: 326: 1357-1361.
169. Randal J. Are mammograms a good idea for AT gene carriers? JNCI 1995: 87: 1351.
170. Lavin M. Role of the ataxia-telangiectasia gene (ATM) in breast cancer. A-T heterozygotes seem to have an increased risk but its size is unknown. BMJ 1998: 317: 486-487.
171. Miller AB. Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ, Risch HA, Preston PL. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 1989: 321: 1285-1289.
172. Council NR. Health effects of exposure to low levels of ionizing radiation, Washington, DC: National Academy Press, 1990, BEIR V.
173. Jones LA, Scott D, Cowan R, Roberts SA. Abnormal radiosensitivity of lymphocytes from breast cancer patients with excessive normal tissue damage after radio-therapy: chromosome aberrations after low dose-rate irradiation. Int J Radial Biol 1995: 67: 519-528.
174. Norman A, Withers HR. Mammography screening for A-T heterozygotes. In: Gatti RA, Painter RB, eds. Ataxia-Telangiectasia, vol H77. Berlin: Springer-Verlag, 1993: 137-140.
175. Rennert G. The value of mammography in different ethnic groups in Israel-analysis of mortality reduction and costs using CAN*Trol. Cancer Detect Prevent 1991: 15: 477-481.
176. Passarge E. Bloom's syndrome: the German experience. Ann Genet 1991: 34: 179-197.
177. Loeffler JS, Harris JR, Dahlberg WK, Little JB. In vitro radiosensitivity of human diploid fibroblasts derived from women with unusually sensitive clinical responses to definitive radiation therapy for breast cancer. Radiation Res 1990: 121: 227-231.
178. Burnet NG, Nyman J, Turesson I, Wurm R, Yarnold JR, Peacock JH. Prediction of normal-tissue tolerance to radiotherapy from in vitro cellular radiation sensitivity. Lancet 1992: 339: 1571-1590.
179. Lavin MF, Bennett I, Ramsay J, Gardiner RA, Seymour GJ, Farrell A, Walsh M. Identification of a potentially radiosensitive subgroup among patients with breast cancer. J Natl Cancer Inst 1994: 86: 1627-1634.
180. Ramsay J, Birrell G. Normal tissue radiosensitivity in breast cancer patients. Int J Radiat Oncol Biol Phys 1995: 31: 339-344.
181. Appleby JM, Barber JB, Levine E, Varley JM, Taylor AM, Stankovic T, Heighway J, Warren C, Scott D. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer 1997: 76: 1546-1549.
182. Ramsay J, Birrell G, Lavin M. Testing for mutations of the ataxia telangiectasia gene in radiosensitive breast cancer patients. Radiother Oncol 1998: 47: 125-128.
183. Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahman N, Ashton A, Moohan M, Wooster R, Owen R, Bliss JM, Stratton MR, Yarnold J. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br J Cancer 1998: 78: 922-927.